Jun 17, 2020
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference
Jun 13, 2020
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
May 14, 2020
Halozyme To Receive $15 Million Milestone Payment From Janssen
May 11, 2020
Halozyme Reports First Quarter 2020 Results
May 07, 2020
Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Apr 30, 2020
Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 26, 2020
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 03, 2020
Halozyme Announces Change Of Location Of Annual Stockholders' Meeting
Feb 26, 2020
Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference
Feb 24, 2020
Halozyme Reports Fourth Quarter and Full Year 2019 Results
Feb 24, 2020
Halozyme Announces CFO Transition
Jan 14, 2020
Halozyme Provides 2020 Business Update And Financial Guidance
Nov 04, 2019
Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology
Sep 23, 2019
Halozyme To Participate In 2019 Cantor Global Healthcare Conference
Sep 13, 2019
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
Aug 06, 2019
Halozyme Reports Second Quarter 2019 Results
Jul 23, 2019
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
Jul 19, 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jul 17, 2019
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology